Mr. Hayakawa was appointed as our board director

Raised 1.6 billion yen through third-party allotment to prepare for clinical trials of ASCL-PLC

Concluded a basic agreement with H.U. Cells, Inc. regarding contracted business for PRP therapy

Notice of Management Change

Raised JPY 152 million through third-party allotment for the early commercialization of ASCL-PLC, a...

The disclosed information of the clinical study has been updated

AdipoSeeds raised 4 million JPY

AdipoSeeds received an acceptance about the compliance of the clinical study to the guideline for t...

The paper of ASCL-PLC was adopted as Plenary Paper of Blood

The patent of manufacturing platelets from adipose tissue-derived mesenchymal stem cell was registe...

AdipoSeeds became an affiliated institution for the research program funded by AMED